Figure 3.
Summary of CMV infections in the first 180 days post-CBT in CBT recipients who did not receive letermovir prophylaxis. aGVHD, acute GVHD; FOS, foscarnet; GAN, ganciclovir; HHV-6, human herpesvirus 6; VALGAN, valganciclovir.
Summary of CMV infections in the first 180 days post-CBT in CBT recipients who did not receive letermovir prophylaxis. aGVHD, acute GVHD; FOS, foscarnet; GAN, ganciclovir; HHV-6, human herpesvirus 6; VALGAN, valganciclovir.
